Abstract
Hemophilia A is a hereditary hemorrhagic disorder characterized by deficiency or dysfunction of the coagulation protein factor VIII. The standard therapy consists of factor VIII replacement, which can lead to the development of neutralizing antibodies (inhibitors), a major complication that implies a burden on patient health and the healthcare system because of the decreased quality of life and further costs with treatment. The current work was to assess the budget impact of a bispecific monoclonal antibody, for patients with inhibitors, considering the Brazilian Public System perspective. Results demonstrated high efficacy on preventing bleeds and savings of R$ 1.5 billion in five years.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
